Microbot Medical Inc (MBOT)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $65.73M
Last updated: Nov 17, 2026 at 4:43 PM ET
Microbot Medical Inc (MBOT) Stock Chart
Microbot Medical (MBOT) has a latest price of $0.69 on Nov 17, 2026, 75.9% below its 52-week high of $2.85. Its price fell 66.7% over the past 12 months. The month-end price fell 90.7% over the 10 years through Oct 2026, a compound annual decline of 21.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $122.49 in Nov 2016 and its lowest $0.88 in Aug 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart MBOT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for MBOT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 55.5%, and over 6 months it fell 60.2%. The month-end price fell 9.2% over the 3 years through Oct 2026, a compound annual decline of 3.2%.
| Period | Change |
|---|---|
| 1 month | -27.7% |
| 3 months | -55.5% |
| 6 months | -60.2% |
| 12 months | -66.7% |
| 12 months, with dividends | -66.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -9.2% | -3.2% |
| 5 years | -84.9% | -31.5% |
| 10 years | -90.7% | -21.1% |
Price by Year
Its best calendar year was 2019, when the price rose 491.3%, and its weakest was 2018, when it fell 88.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.09 | -45.5% |
| 2025 | $2.00 | +78.6% |
| 2024 | $1.12 | -31.7% |
| 2023 | $1.64 | -45.5% |
| 2022 | $3.01 | -59.9% |
| 2021 | $7.50 | +8.9% |
| 2020 | $6.89 | -32.3% |
| 2019 | $10.17 | +491.3% |
| 2018 | $1.72 | -88.8% |
| 2017 | $15.29 | -83.3% |
Trading Range
The price is 39.2% below its 50-day average of $1.13 and 61.5% below its 200-day average of $1.79.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.69 | |
| 52-week high | $2.85 | -75.9% |
| 52-week low | $0.52 | +32.0% |
| 50-day average | $1.13 | -39.2% |
| 200-day average | $1.79 | -61.5% |
Price Risk
Over 3 years, its largest fall from a peak was 85.7%.
| Measure | Value |
|---|---|
| 1-year beta | 2.00 |
| Largest fall, 1 year | -77.4% |
| Largest fall, 3 years | -85.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About MBOT
What is MBOT's 1-year price change?
Microbot Medical's price fell 66.7% over the past 12 months. With dividends included, the 12-month total return was -66.7%.
What is MBOT's 5-year price change?
Microbot Medical's month-end price fell 84.9% over the 5 years through Oct 2026, a compound annual decline of 31.5%. These figures leave out dividends.
What is MBOT's 52-week high and low?
Microbot Medical's 52-week high is $2.85 and its 52-week low is $0.52. Its latest price of $0.69 on Nov 17, 2026 is 75.9% below the high.
What is MBOT's beta?
Microbot Medical's 1-year beta against the S&P 500 is 2.00, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 77.4%.
Is the MBOT chart free?
Yes. Advanced Charting for MBOT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
MBOT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors